GENB 是高风险投资，尽管 Nvidia 近期入股，但存在大量现金消耗和极端估值倍数；说话者对其排名较低。
逐段跳播
我觉得这只股票确实暗示了 Jensen Huang 可能看到 AI 在药物发现领域的下一个前沿，即 Generate Biomedicine，股票代码 GENB，Nvidia 最近买入了约 1400 万美元的股票。
Uh, this stock really, I feel hints at where Jensen Huang might be seeing the next frontier of AI in drug discovery with Generate Biomedicine, ticker symbol GENB, GenB, which Nvidia just recently picked up around $14 million worth.
然而，这仍然只占其投资组合的约 0.02%。这就是他们的规模。但是，你知道，与 Nvidia 在半导体上花费的数十亿美元相比，这里的 1400 万美元听起来可能像是零花钱，但直接投资于临床阶段的生物技术公司实际上是一个值得关注的重大信号。
Yet, that's still only about uh, 0.02% of their portfolio. That's how big they are. But, you know, compared to the billions that they spend on that Nvidia spends on semiconductors, uh, $14 million here might sound like pocket change for Nvidia, but investing directly into a clinical stage biotech is actually a pretty big signal to track.
Generate 正在开创他们所谓的可编程生物学，与旧式制药方法随机测试数千种化合物并希望其中一种有效不同，他们转而使用机器学习模型从头设计一切，并在分子进入实体实验室之前，用数字方式测试这些分子将如何与疾病相互作用，这旨在大幅缩短临床试验所花费的时间和数十亿美元。
See, Generate is pioneering what they call programmable biology, where instead of the old pharma methods of randomly testing thousands of compounds and hoping that one of them works. Well, they instead use machine learning models to design everything from scratch and then digitally test how these molecules will interact with a disease before it ever even hits a physical lab, which is designed to drastically cut down the time and the billions of dollars spent in clinical trials.
目前，他们的主要候选药物 GB0895 是一种治疗哮喘和慢性阻塞性肺病的药物，已进入三期试验。其独特之处在于设计为每年仅注射两次，号称近乎……
Now, right now, their lead candidate, GB0895, is an asthma and COPD treatment that is already in phase three trials. And what makes it so unique is that it's designed to be injected just twice a year, boasting a nearly
此外，他们还有一个完全独立的肿瘤学项目进入一期，该项目作为一种中和剂，基本上捕获其他化疗药物的有毒载荷，以阻止许多严重的副作用。这可能是一个真正的改变游戏规则的因素。
Now, on top of that, they have a completely separate oncology program entering phase one that acts as a neutralizer, basically capturing the toxic payloads from other chemotherapy drugs to stop much of the severe side effects. That could be a real game-changer.
这相当具有突破性，但不幸的是，对于投资者来说，该公司仍在大量烧钱，仅上个季度就公布了超过 6000 万美元的净亏损。
That's pretty breakthrough stuff, but unfortunately for investors, the company is still burning through huge amounts of cash and posted a net loss of over $60 million last quarter alone.
因此，他们的估值指标高得离谱，尽管自 IPO 以来仅上涨约 26%，但其远期市销率仍比医疗保健行业高出 1000% 以上。
As a result, their valuation metrics are sky-high where despite only climbing about 26% since IPO, their forward price-to-sales ratio is still over 1,000% higher than the healthcare sector.
未来，这一数字可能会大幅下降，尤其是如果他们任何有前景的药物能够上市，这当然是一个非常现实的可能性。当然，拥有 Nvidia 的信任和支持也带来了很多可信度。
And in the future, this will likely come down dramatically, especially if any of their promising drugs are able to reach market, which is a very real possibility, of course. And certainly having the trust and backing of Nvidia leads to, you know, much of that credence, too.
但对我来说，我已经持有太多生物科技股了，而这一只很可能我们今天列表中最具风险的选择之一。所以，我暂时会将其排在较低的位置，即第六位，直到我们看到其他持仓并逐一分析。
But for me, I already own too many biotechs as it is, and this one is very likely one of the riskiest options of our list today. So, I'm going to rank them pretty low for now at number six until we see the other holdings and run through them.
这个频道对 $GENB 的历次判断
Ale's World of Stocks 在这只股票上只有这一条判断。